Press Releases

Filter Press Releases:



  • Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo

    INDIANAPOLIS, Feb. 15, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM - a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) - were published in the New England Journal of Medicine. The New England Journal of Medicine publication includes supplemen…

  • European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis

    Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to…

  • Lilly To Present At Leerink Partners Global Healthcare Conference

    INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will participate in a fireside chat at 1:30 p.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Pr…

  • Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors

    INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the Science and Technology and Public Policy and Compliance Committees of the board. Professor Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry an…

  • Lilly to Present at Cowen Health Care Conference

    INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017. David A. Ricks, Lilly's president and chief executive officer, will speak at 8:40 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at http…

  • Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes

    INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ -- The label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. The U.S. Food and Drug Administration (FDA) included the changes to the approved product labeling to reflect this important information for prescribers. Trulicity is a…

  • Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents

    INDIANAPOLIS, Feb. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in Lilly's favor in the invalidation trials initiated by Sawai regarding Lilly's vitamin regimen patents for Alimta. In the fourth quarter of 2015, the Japan Patent Office issued written decisions upholding the v…

  • Lilly Reports Fourth-Quarter and Full-Year 2016 Results

    INDIANAPOLIS, Jan. 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2016.   $ in millions, except per share data Fourth Quarter % Full Year % 2016 2015 Change 2016 2015 Change Revenue $ 5,760.5…

  • Lilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement

    INDIANAPOLIS, Jan. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a call for investors, media and the general public at 11:30 a.m. Eastern Time on January 31, 2017 to discuss the company's fourth-quarter and full-year 2016 financial results. Originally, the call had been scheduled to begin at 9:00 a.m. Eastern Time. A live webcast of the conference call will be available thr…

  • Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid

    INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly's existing portfolio in pain management for migraine, while adding a potential near-term launch to…

  • U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment

    INDIANAPOLIS, Jan. 13, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA). The NDA for baricitinib was su…

  • U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent

    INDIANAPOLIS, Jan. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding validity and infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). In the case of Eli Lilly and Company v. Teva Parenteral Medici…

  • Lilly and Merck Expand Immuno-Oncology Collaboration

    INDIANAPOLIS, Jan. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, through a subsidiary, to add a new study of Lilly's LARTRUVO™ (olaratumab) with KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarc…

  • Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement

    INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, medi…

  • Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities

    INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Explaining the need for these changes, David A. Ricks, Lilly's president and CEO, said, "Lilly begins 2017 with a clear view of its opportunities for growth in the years ahead.…

  • U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empa

    RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 4, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark EMPA-REG OUTCOME® trial. The data show that empagliflozin reduced the risk for cardiovascular death compared with placebo when added to sta…

  • Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio

    GREENFIELD, Ind., Jan. 3, 2017 /PRNewswire/ -- Today Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), announced that it has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc's (BIVI) U.S. feline, canine and rabies vaccines portfolio - as well as a fully integrated manufacturing and R&D site and several pipeline assets. The acq…

  • Lilly to Present at J.P. Morgan Healthcare Conference

    INDIANAPOLIS, Jan. 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017. David A. Ricks, Lilly's president and chief executive officer, will make a formal presentation from 7:30 p.m. to 7:55 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of L…

  • Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards

    RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 16, 2016 /PRNewswire/ -- The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use of Jardiance® (empagliflozin) tablets in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death. The updated recommendations,…

  • CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

    INDIANAPOLIS, Dec. 16, 2016 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib - which if approved would be marketed as Olumiant®. Baricitinib would be indicated for the treatment…

  • BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.

    INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. announced today that BASAGLAR® (insulin glargine injection 100 units/mL) is available by prescription in the U.S. BASAGLAR is a follow-on insulin to Lantus®. It is a long-acting insulin with an amino acid sequence identical to Lantus, another…

  • Lilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade

    INDIANAPOLIS, Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its 2017 financial guidance and highlighted key events for the upcoming year. The company reaffirmed its financial expectations through the remainder of the decade, including at least 5 percent average annual revenue growth driven by volume and an increase in gross margin as a percent of revenue, both on…

  • Lilly Announces Program to Provide Insulin at Discounted Prices

    INDIANAPOLIS, Dec. 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January 1, 2017 via mobile and web platforms hosted by Blink Health. The discounts, provided by Lilly through a partnership with Express Scripts (NASDAQ: ESRX), may reduce costs for people who pay full…

  • Lilly Announces Dividend Increase

    INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The dividend for the first quarter of 2017 will be $0.52 per share on outstanding common stock. This raises the annual indicated rate to $2.08 per share.  The dividend is payable March 10, 2017, to shareholders of record at of…

  • Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease

    INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as a potential disease-modifying treatment for Alzheimer's disease (AD). This agreement builds on the existing collaboration related to AZD3293, a BACE inhibi…

  • Lilly Confirms Date and Conference Call for 2017 Financial Guidance Announcement

    INDIANAPOLIS, Dec. 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2017 and provide updated financial guidance for 2016 on Thursday, December 15, 2016. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance. The conference call will begin at 10 a.m. ET. I…

  • Lilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students

    INDIANAPOLIS, Nov. 30, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will deepen its partnership with Florida Agricultural and Mechanical University (FAMU) and Howard University with the inaugural Sybil C. Mobley Scholars Program and the inaugural H. Naylor Fitzhugh Scholars Program. The programs, in part, aim to increase the representation of diverse talent in Lilly's marketing organizat…

  • Lilly Reports Third-Quarter 2016 Results

    INDIANAPOLIS, Oct. 25, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2016. $ in millions, except per share data Third Quarter % 2016 2015 Change Revenue $ 5,191.7 $ 4,959.7 5% Net Income - Reported 778.0 799.7 (3)…

  • Lilly Announces Ambitious New Commitment to Expand Global Access to Health Care

    INDIANAPOLIS, Oct. 18, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an ambitious plan to increase access to quality health care and to improve long-term health for millions of people worldwide. Through investments in people, medicines and health systems, Lilly aims to reach 30 million people in resource-limited settings annually by 2030. The cornerstone of this goal - kn…

  • Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative

    INDIANAPOLIS, Oct. 17, 2016 /PRNewswire/ -- With the global prevalence of new cancer cases expected to rise by 70 percent during the next two decades, representatives from government, academic, pharmaceutical and diagnostic companies are pooling their knowledge to accelerate treatments to patients.1 Today, Eli Lilly and Company (NYSE: LLY) announced it will contribute cancer research data to the…

  • Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community

    INDIANAPOLIS, Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA) by giving them tools, education and resources, allowing them to expect more from their RA treatment - seeking remission or low disease activity as the only acce…

  • Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana

    INDIANAPOLIS, May 19, 2016 /PRNewswire/ -- A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and health volunteers as part of Lilly's Connecting Hearts Abroad global employee volunteer program. A second team of volunteers will depart next week to serve in Ghana. Nine more teams of Lilly volunteers will…

  • Lilly and United Way Celebrate Deepening Partnership, Community Impact

    INDIANAPOLIS, Nov. 5, 2015 /PRNewswire/ -- Representatives from Eli Lilly and Company (NYSE: LLY) and United Way and its partner agencies gathered today to celebrate the early success of a new partnership approach that includes pairing Lilly teams with United Way agencies and a record gift of $13 million. The results will be shared today from 4-6 p.m. at an Impact Celebration event hosted at the…

  • Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

    ROLLING MEADOWS, Ill. and INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a chronic disease such as diabetes in check can make an exciting time much more challenging. Today, the Diabetes Scholars Foundation (Foundation) announced its 2015 college scholarship rec…

  • Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes

    INDIANAPOLIS, June 8, 2015 /PRNewswire/ -- Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of perseverance and triumph as part of the Lilly Camp Care Package (LCCP) program. Kris and Ryan will speak to children at select diabetes summer camps about how type 1 diabetes did not stop them from chasing…

  • Lilly commits 780,000 additional vials of insulin to Life for a Child

    INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) i…

  • Lilly Sends Employees to Serve in Vulnerable Communities around the World

    INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY), believes his volunteer work in a healthcare setting in Bangkok, Thailand, will be among the most humbling experiences of his life. "Caring for people in need with respect and dignity is the guiding star for me and my fellow volunteers," sh…

  • Lilly Releases Corporate Responsibility, Global Health Reports

    INDIANAPOLIS, May 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released two new reports that provide a comprehensive overview of the company's corporate responsibility efforts. The reports highlight how Lilly is evolving its approach to corporate responsibility by increasingly leveraging its assets and capabilities in partnership with others to have greater, more sustainable im…

  • Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America

    Full Commercialization Rights Transferred to Lilly INDIANAPOLIS & NEW YORK--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE:LLY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have agreed to transfer rights to Erbitux® (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Br…

  • The Lilly Foundation Commits $1 Million to Support AMPATH Oncology Institute in Kenya

    INDIANAPOLIS, Feb. 4, 2015 /PRNewswire/ -- In conjunction with World Cancer Day, Eli Lilly and Company (NYSE: LLY) announced a commitment of $1 million to AMPATH in Eldoret, Kenya. The funding, provided by the Lilly Foundation, will help equip a new oncology center, hire additional staff and train local healthcare professionals—ultimately allowing AMPATH to screen, treat and provide palliat…